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The pivotal role of TAMs in PNETs has not been elucidated yet. Based on the 
assessment of TAM infiltration in more than 100 human specimens of metastatic and 
nonmetastatic, functional active and nonfunctional active PNETs, we characterized 
their impact on tumor progression. Moreover, TAMs are associated with increased 
proliferation and angiogenesis in the RIP1Tag2 neuroendocrine mouse model. 
Targeting TAMs in this mouse model with the liposomal bisphosphonate clodronate 
led to a significant disruption of tumor progression. These findings indicate that TAMs 
play a major role in mediating acquired resistance to targeted antiangiogenic 
therapies and represent a novel therapeutic avenue to target tumor progression and 
drug resistance in PNETs. 
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Pancreatic neuroendocrine tumors (PNETs) represent a heterogeneous group of 
neuroendocrine neoplasms with varying biological behaviour and response to 
treatment. Although targeted therapies have been shown to improve the survival for 
patients at advanced stage, resistance to current therapies frequently occurs during 
the course of therapy. Previous reports indicate that the infiltration of tumor
associated macrophages (TAMs) in PNETs might correlate with tumor progression 
and metastasis formation. We aimed to evaluate the prognostic and functional impact 
of TAMs in human PNETs   and   and to investigate the effect of 
therapeutic targeting TAMs in a genetic PNET mouse model TAM expression pattern 
was assessed immunohistochemically in human PNET tissue sections and a tissue
microarray of PNET tumors with different functionality, stage and grading. The effect 
of liposomal clodronate on TAM cell viability was analysed in myeloid cell lines and 
isolated murine bone macrophages (mBMM). 	 , RIP1Tag2 mice developing 
insulinomas were treated with liposomal clodronate or PBSLiposomes. Tumor 
progression, angiogenesis and immune cell infiltration were assessed by 
immunohistochemistry.  
In human insulinomas TAM density was correlated with invasiveness and malignant 
behaviour. Moreover, TAM infiltration in liver metastases was significantly increased 
compared to primary tumors. 	 , liposomal clodronate selectively inhibited the 
viability of myeloid cells and murine bone macrophages, leaving PNET tumor cell 
lines largely unaffected. 	 , repeated application of liposomal clodronate to 
RIP1Tag2 mice significantly diminished the malignant transformation of insulinomas, 
which was accompanied by a reduced infiltration of F4/80 positive TAM cells and 
simultaneously by a decreased microvessel density, suggesting a pronounced effect 
of clodronateinduced myeloid depletion on tumor angiogenesis. Concomitant 
treatment with the antiangiogenic TKI sunitinib, however, did not show any 
synergistic effects with liposomal clodronate. TAMs are crucial for malignant 
transformation in human PNET in particular in insulinomas and correlate with 
metastatic behaviour. Pharmacological targeting of TAMs via liposomal clodronate 
disrupts tumor progression in the RIP1Tag2 neuroendocrine tumor model and was 
associated with reduced tumor angiogenesis Based on these results, using liposomal 
clodronate to target proangiogenic myeloid cells could be employed as novel 
therapeutic avenue in highly angiogenic tumors such as PNET.   
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During the last decade, the predominant role of the tumor microenvironment (TME) 
as modulator of tumor progression has been increasingly recognized. Nonmalignant 
stromal cells may not only facilitate tumor initiation, disease progression and 
metastasis, but are also affecting response or resistance to various therapeutic 
strategies. The TME comprises stromal cells such as endothelial cells, fibroblasts as 
well as various immune cell populations 1. Both lymphoid and myeloid lineages are 
modulating tumorigenesis and tumor progression, with impact on tumor cell 
proliferation, invasion and survival as well as effects on the immunogenicity of the 
tumor 2, 3. Within the myeloid compartment, tumorassociated macrophages (TAMs) 
represent an important fraction. Numerous studies have demonstrated an inverse 
correlation between patient prognosis and TAM infiltration in various tumor entities, 
among them Hodgkin’s lymphoma, breast cancer, glioblastoma and pancreatic 
cancer 47. The functional impact of TAMs is still incompletely understood. TAMs 
release miscellaneous cytokines and proteases, among them proangiogenic factors 
such as VEGF as well as various cathepsins 810. In addition to their profound effects 
on tumor progression, TAMs equally affect the efficacy of cancer therapy and the 
effects of therapeutic irradiation and targeted antiangiogenic treatment are modulated 
by TAMs which may acquire different functional states during tumor initiation, 
progression and therapeutic intervention. TAM functional plasticity has been 
categorized in two different opposing polarization states, M1 and M2. Generally, M1 
macrophages secrete proinflammatory cytokines with antineoplastic effects while 
M2 macrophages produce antiinflammatory signals which facilitate tumor 
progression 11, 12. However, it is noteworthy that this classification is oversimplified 
and does not fully represent the complexity of TAM action.  
Pancreatic neuroendocrine tumors (PNETs) represent a heterogeneous tumor entity 
within the group of neuroendocrine neoplasms. From a clinical point of view, patients 
with functionally active PNETs (FAPNETs) such as insulinomas are mainly 
diagnosed at early stages, whereas nonfunctional PNETs (NFPNETs) often present 
with symptoms when distant metastases have already occurred 13. Several 
clinicopathological features have been linked to poor overall survival, including 
performance status, age, differentiation and proliferation capacity (Ki67 index) 1416. 
In recent years, effort has been made in deciphering the genetic basis of PNETs. 
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Commonly mutated genes include MEN1, DAXX, ATRX and members of the mTOR 
pathway 17. Recently, wholegenome sequencing results of more than 100 PNETs 
were presented by Scarpa and coworkers. In this landmark paper novel germline 
mutations in the genes MUTYH, CHEK2 and BRCA2 were described 18. Moreover, 
distinct subgroups with altered somatic mutations were identified, including chromatin 
remodelling, DNA damage repair, activation of mTOR signalling (DEPDC5 and 
EWSR1) and telomere modification 18.  
The influence of infiltrating immune cells in neuroendocrine tumors has not been 
completely elucidated yet. In humans, infiltration of TAMs in primary PNETs 
correlates with proliferative activity, presence of liver metastases and disease 
recurrence after curative surgery 19, 20. Preclinical studies to decipher the role of 
immune cells were performed using the RIP1Tag2 genetically engineered mouse 
model for pancreatic neuroendocrine tumors. This model faithfully recapitulates the 
multistep process of insulinoma transformation, including the stages of hyperplastic 
islets, angiogenic islets, and invasive tumors with various gradings 21. When tissue 
bound macrophages were constitutively depleted in RIP1Tag2 mice via genetic CSF
1 deficiency the tumor burden decreased markedly 19.  
Mechanistically, TAMs modulate the tumor micromilieu via secreting multiple 
mediators of angiogenesis and invasiveness such as VEGF, heparanase and 
cathepsins 9, 2224. To overcome TAM mediated disease progression, clinically 
feasible therapeutics are mandatory. To this end, we utilized liposomal clodronate as 
pharmacological tool to target TAMs in the RIP1Tag2 model. Moreover, in two large 
series of FA and NFPNETs and in primary and distant metastatic sites CD68 
positive macrophages were assessed to study the association between TAM 
infiltration and tumor progression in humans.  
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Human neuroendocrine Bon1 and QGP1 cells were a kind gift of R. Göke, University 
of Marburg, Germany (25, passage 1030) and cultured in DMEM/HAM's F12 
medium.  J774 and RAW cells were obtained by ATCC and cultured in Dulbecco's 
modified Eagle's medium (GIBCO) supplemented with 10% FCS. All media contained 
10% fetal bovine serum and 40 Lg/ml gentamicin. All cells were cultured in a 
humidified atmosphere containing 5% CO2 at 37°C. 
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Ki67 proliferation index was evaluated according to a standardized protocol using 
LeicaBondMaxAutostainer and the Ki67 antibody from Dako at a dilution of 
1:1000. In addition, CD31 (1:20; Dianova; Hamburg, Germany) and CD68 (Dako, 
1:100) antibodies were used. Antibody binding was visualized using a biotinylated 
secondary antibody, avidinconjugated peroxidase (ABC method; Vector 
Laboratories), 3,39 diaminobenzidine tetrachloride (DAB) as a substrate, and H&E as 
counterstain.  
Immunohistochemical staining for CD3 (1:500; abcam), F4/80 (1:50; abDSerotec, 
BioRad), Caspase3 (1:100; Cell Signaling), SV40Tantigen V300 (1:100; Cell 
Signaling), FOXP3 (1:50; Affymetrix) and Arginase I (1:50; Santa Cruz) was 
performed using LeicaBondRX. Visualization was performed using Bond Polymer 
Refine Detection and H&E as counterstaining. 
The insulinoma tissue samples (FFPE) were obtained from the neuroendocrine tumor 
archives of the Departments of Pathology in Zürich (Switzerland), Düsseldorf 
(Germany) and Kiel (Germany) from 1975 – 2006 according to the guidelines of the 
local ethics committees. 1.5mm tissue cores were taken from representative areas 
and inserted into four paraffin blocks. The 4 MTAs contained a total of 286 cores and 
additional human tonsil orientation/control cores. The construction was performed 
using MTA1 tissue arrayer equipment (Beecher Instruments, Sun Prairie, WI, USA). 
MTAs were routinely processed for paraffin sectioning. Paraffin sections were 
deparaffinized, rehydrated and immunohistochemical stains were performed 
according to routine methods. The analysis was performed by a pathologist with 
expertise in endocrine and pancreatic tumors (B.S.) in a blinded fashion concerning 
clinical tumor parameters.  
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The RIP1Tag2 transgenic mouse model has been previously described 21, 26, 27. 
RIP1Tag2 mice were generated and maintained in a C57BL/6 background. No 
glucoseenriched food or water was offered to diminish the risk of hypoglycemia. 
Liposomal clodronate and PBSLiposomes were obtained from Dr N Van Rooijen 
(Vrije Universiteit, Amsterdam, Netherlands). Liposomal clodronate was injected 
intraperitoneally twice per week at concentrations of 1.4mg/20mg body weight. 
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Sunitinib malate was purchased from Cayman chemical (Ann Arbor, USA) and 
administered daily by oral gavage at concentrations of 40 mg/kg/d. All animal 
experiments were approved by the local government authorities and performed 
according to the guidelines of the animal welfare committee. 
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The comparisons between macrophage infiltration, tumor response and 
histopathological characteristics, disease stage and laboratory features were 
performed based on Chisquare and Fisher’s exact tests, as appropriate. 
Recurrencefree survival was measured from surgery to recurrence, diseaserelated 
death, or last followup. OS was measured from the beginning of treatment to the 
time of last followup or death. Actuarial survival was measured by the method of 
Kaplan and Meier 28. All data are presented as mean ± standard error deviation. Two
tailed paired Student's t test was used for statistical evaluation of the data. The one
way and nonparametric ANOVA test was used to calculate the p value for more than 
two groups.  A p value < 0.05 was considered significant. All statistical calculations 
were performed using SPSS (IBM SPSS Statistics) and graph pad prism (GraphPad 
software, La Jolla, USA). 
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TAM infiltration was initially assessed in a cohort of PNET tissues including 21 
insulinomas as well as 11 nonmetastatic NF tumors and 13 metastatic NF tumors 
(Figure 1A). Baseline characteristics of all patients within this cohort are given in 
Table 1. As expected due to earlier presentation with symptoms, insulinoma patients 
were younger than NFPNET patients, which was independent of the presence or 
absence of distant metastases (median age: 48 vs. 54 vs. 58 years, table 1). 
Likewise, higher grading significantly correlated with metastatic behaviour (G1 1 
metastatic vs. 9 nonmetastatic, G2 12 metastatic vs. 2 nonmetastatic tumors; 
P=0.006), confirming the influence of proliferation on disease progression. In this 
cohort, CD68 positive macrophages were counted in at least 10 HPF. Representative 
immunohistochemical stainings are shown in Figure 1B. Mean TAM infiltration in 
primary tumors did not differ between insulinomas, metastatic NFPNET and non
metastatic NFPNET (163, 170 and 133 CD68+ cells / 10 HPF, respectively) (Fig. 
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1C). In contrast, TAM infiltration in metastases (430 CD68+ cells / 10 HPF) was 
markedly higher compared to primary tumor tissues, with significance being reached 
in comparison to insulinomas and nonmetastatic NFPNETs (P=0.004 and P=0.021) 
(Fig. 1C). Comparison of the FNAPNET metastases to primary FNAPNET tumor 
tissues (only 1 paired and 3 independent primary tumor samples) did not reach 
significance due to a small number of samples of available primary FNAPNET 
tissues (P=0.082) (Fig. 1C). None of the patients with metastatic disease received 
antiresorptive therapy with bisphosphonates. 
In subgroup analyses, no correlation between TAM infiltration and patient age, tumor 
grading, Ki67 or recurrencefree survival was detected, most likely due to small and 
heterogeneous sample sizes. Thus, we decided to assess TAM infiltration in an 
independent larger cohort. For this purpose, a multipletissuearray (MTA) was used 
comprising 83 tissue with benign and malignant insulinomas and normal peritumoral 
exocrine pancreatic tissues as internal controls. Histopathological characteristics of 
the patients are presented in supplementary table 1. Twelve patients with 
neuroendocrine carcinomas and 48 patients with welldifferentiated tumors and/or 
metastases were included.  The mean density of TAMs was 29, 43 and 234 CD68+ 
cells / 10 HPF in peritumoral exocrine pancreas, benign and malignant insulinomas, 
respectively (Figure 2B, P<0.001), indicating a significant correlation between 
increased macrophage infiltration and tumor progression (Figure 2A). The group of 
malignant insulinomas comprised 7 primary tumors, 5 infiltrated lymph nodes and 7 
liver metastases. The highest infiltration of TAMs has been detected in liver 
metastases with a mean of 315 CD68+ cells / 10 HPF (P<0.05 compared to primary 
tumors and lymph nodes with 178 and 145 CD68+ cells, respectively). Moreover, the 
infiltration of CD68+ cells was significantly higher in malignant compared to benign 
insulinomas (43 vs. 178; P<0.01, Figure 2B). Similarly, poor differentiation defined as 
G3 neuroendocrine carcinomas (NEC) was associated to higher CD68+ macrophage 
infiltration compared to welldifferentiated tumors (NEC vs. NET, 243 vs. 40 CD68+ 
cells, P<0.0001). The clinical correlation of these findings showed that in 6 out of 12 
patients with NEC a diseaserelated death (DRD) occurred with a median overall 
survival of 27 months. In these patients, the CD68 score reached 303 positive cells 
on average. No DRD was documented in the group of patients with welldifferentiated 
tumors.  
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To investigate a possible association between TAMs and PNET progression, we 
assessed TAM infiltration via F4/80 staining, the Ki67 index and microvessel density 
via CD31 staining during the course of disease in the RIP1Tag2 transgenic mouse 
model. Representative slides for F4/80, Ki67 and CD31 are shown in Supplemental 
Figure 1A. Sequential stages of hyperplastic (n = 17), angiogenic (n = 22) and 
invasive tumors (n = 18) demonstrated increased proliferation of tumor cells (mean 
Ki67 values: 9%, 28% and 67%; Supplemental Figure 1C; P<0.001). The tumor 
stagedependent proliferation was paralleled by a significantly increasing number of 
microvessels in hyperplastic (n = 16), angiogenic (n = 20) and invasive tumors (n = 
20) (mean values CD31 positive cells / HPF: 11, 31 and 74; Supplemental Figure 1D; 
P<0.001). In analogy to these findings, infiltrating TAMs have been investigated in 
hyperplastic (n = 25), angiogenic (n = 12) and invasive tumors (n = 15): The mean 
numbers of F4/80+ cells / 10 HPF increased from 7 (hyperplastic) to 35 (angiogenic) 
and 85 (invasive tumors) (Supplemental Figure 1B; P<0.001), indicating an 
increasing infiltration of TAMs during the tumor progression. 
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To elucidate the impact of therapeutic TAM modulation on tumor progression, 
liposomal clodronate has been used as an effective pharmacological tool to deplete 
macrophages in various   models including a mouse model of pancreatic 
adenocarcinomas 29.  
To evaluate the specificity of liposomal clodronate to target TAMs, we first 
investigated the susceptibility of several murine myeloid cell lines and human 
pancreatic neuroendocrine tumor cell lines to liposomal clodronate  . To this 
extent, the myeloid cell lines J774, RAW and primary murine bone marrowderived 
macrophages (mBMMs) from nontransgenic C57BL/6 mice as well as the 
neuroendocrine tumor cell lines Bon1 and GQP1 were utilized. While no effect on 
cell viability was detected in the tumor cell lines, liposomal clodronate significantly 
affected cell viability of all investigated myeloid cells with a reduction of cell viability 
ranging between 39% and 87% after 24 hours (Figure 3).  
	 studies to evaluate the impact of liposomal clodronate on PNET tumorigenesis 
and tumor progression were performed using the transgenic RIP1Tag2 model. Based 
on the multistage tumor progression in this model, we used two different 
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pharmacological intervention schemes with liposomal clodronate that allowed us to 
assess its effects both on the angiogenic switch during tumorigenesis (“prevention 
trial”) and on the tumor progression (“intervention trial”). In the prevention trial, mice 
harbouring normal and hyperplastic islets were treated from week 6 to 13, while in 
the intervention trial mice were treated from week 9 to 16 (Figure 4A). Liposomal 
clodronate effectively decreased the number F4/80+ macrophages during tumor 
progression as shown in Supplemental Figure 2. In the prevention trial, liposomal 
clodronate reduced the cumulative tumor burden at week 13 significantly by 62% 
compared to PBSliposomes (6.9x106 µm2 vs. 2.6x106 µm2; P=0.036, Table 2). While 
the number of hyperplastic, angiogenic and invasive islets remained unchanged in 
both groups, clodronate completely prevented the development of invasive tumors in 
4 of 10 mice (P=0.025).  
In the intervention trial, the influence of liposomal clodronate on tumor progression 
(number of invasive tumors: mean 4.6 vs. 2.2 per mice, P=0.069) and tumor volume 
(12.7x106 µm2 vs. 10.2x106 µm2, P=0.47) was less pronounced and did not reach 
statistical significance. Therefore, we speculated that TAMs are particularly important 
in early tumorigenesis during the progression from angiogenic to invasive islets. To 
further address this hypothesis, we assessed microvessel density (MVD) as cardinal 
feature of the angiogenic switch using CD31 immunhistochemistry as well as 
proliferation (Ki67) and apoptosis marker (cleaved caspase3). No differences 
between verum and placebotreated animals were detected for Ki67 and cleaved 
caspase3 (Table 2). In contrast, CD31+ cells in invasive tumors were dramatically 
diminished in the intervention trial (39 vs. 22 positive cells per HPF, P=0.006) with a 
similar trend also in the prevention trial (77 vs. 48 positive cells per HPF, P=0.08). 
This indicates that angiogenesis is a critical step in mediating progression to invasive 
tumors, which is affected by macrophage depletion using liposomal clodronate. In 
order to characterize the depletion of F4/80+ cells more thoroughly, particularly 
effects on macrophage polarisation, we assessed arginase expression by 
immunohistochemistry as established marker for the protumoral M2 polariation of 
macrophages. Interestingly, no change was seen between liposomal clodronate and 
PBSLiposomes treated mice, indicating that both M1 and M2 polarized 
macrophages are targeted by lipocomal clodronate. 
Since depletion of F4/80+ macrophages may also affect T cell populations, we also 
stained the T cell marker CD3 and the marker for regulatory T cells FOXP3. In late 
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tumor stages clodronate application fostered the infiltration of CD3 positive cells 
(mean: 9 vs. 15 positive cells per HPF, P=0.034) in the intervention group. However, 
at earlier tumor stages this effect was not present and FOXP3 positive T cells were 
not regulated in both prevention and intervention cohorts (Table 2). Supplemental 
Figure 3 depicts representative stainings of Caspase 3, CD3, FOXP3 and Arginase in 
different tumor stages and lymphnodes. 
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Primary or acquired resistances frequently limit the efficacy of systemic 
antiangiogenic therapies such as sunitinib in PNET patients during the course of the 
disease. In preclinical models including the RIP1Tag2 mouse model previous reports 
proposed sunitinibinduced activation of escape mechanisms such as hypoxia, 
epithelialmesenchymal transition (EMT), and other hypoxiadependent signalling 
pathways 3032 as mediators of resistance, thereby accelerating tumor aggressiveness 
and metastasis formation. Based on these data, we aimed to examine whether these 
escape mechanisms to antiangiogenic drugs can be overcome by targeting 
macrophages (Figure 4B). 
First, we treated RIP1Tag2 mice with sunitinib monotherapy from week 12 to 16. 
Thereby, we could confirm that sunitinib resulted in remarkable reduction of 
microvessel density measured using an AntiCD31 antibody (Table 3). However, no 
differences could be detected in terms of tumor number and volume (Table 3). In 
contrast to previous reports no liver metastases could be detected by H&E staining 
and immunohistochemistry using an SV40 antibody (data not shown). However, in 
the sunitinib group all mice (n=10) survived the treatment period, whereas two of ten 
mice in the placebo cohort died before sacrifice, potentially emphasizing a 
biochemical response during therapy via reducing insulin levels, although statistical 
significance was not reached due to small sample size. 
Furthermore, we depleted macrophages via liposomal clodronate from week 9 to 16 
and simultaneously administered sunitinib (from week 12 to 16). Combination 
treatment resulted in a significant reduction of both microvessel density (mean: 39 vs. 
15 positive cells per HPF, P<0.001) and infiltrating TAMs (mean: 47 vs. 24 positive 
cells per HPF, P=0.003) (Table 3). However, no statistically significant synergies of 
dual antiangiogenic treatment regarding number of invasive islets or tumor volumes 
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compared to monotherapy could be detected. Likewise, no differences in proliferation 
and apoptosis markers or infiltrating CD3+, FOXP3+ or Arginase+ cells have been 
observed between combination and monotherapy strategies (Table 3). Similar to 
sunitinib monotherapy more mice reached the study endpoint of 16 weeks in the 
combination arm (9 vs. 6) compared to placebo therapy, however, this study has not 
been designed to evaluate overall survival.  
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In this study, we utilized two independent cohorts of functionalactive and non
functional active PNET tissue samples to investigate the infiltration of TAMs and its 
impact on tumor progression and metastasis. Our data clearly show that infiltrating 
TAMs are significantly correlated to tumor hallmarks such as angiogenesis, 
proliferation and metastasis. In addition, this study introduces liposomal clodronate 
as new therapeutic tool to target macrophages in pancreatic neuroendocrine tumors. 
Liposomal clodronate by depleting TAMs significantly impaired angiogenesis in the 
RipTag2 genetic mouse model of PNET. Our data suggest that pharmacological 
depletion of TAMs could serve as a suitable new therapeutic avenue for patients with 
unresectable disease. However, dual targeting of angiogenesis by simultaneous use 
of the clinically established multityrosine kinase inhibitor sunitinib and liposomal 
clodronate in RIP1Tag2 mice failed to show synergistic antitumor or antiangiogenic 
efficacy. 
Recently, TAMs were assessed in human PNETs samples with the degree of 
infiltration strongly correlating to proliferative activity, tumor grade and stage 19. 
However, this study included only a small and heterogeneous patient cohort with 22 
functional nonactive (NF) and 5 functionally active (FA) PNETs without detailed 
characterization. TAM infiltration was only investigated in primary tumor samples. In 
our study, we used two independent cohorts of PNET including both primary tumors 
and metastases. In the first cohort, we could detect a remarkable difference between 
TAMs in primary tumors and distant metastases. However, this cohort also included 
heterogeneous tumor entities, both functionally active and nonactive. Therefore, we 
aimed to confirm our data in a more homogeneous PNET cohort and used a TMA 
comprising benign and malignant insulinoma tissues including lymph node and liver 
metastases. Hereby, we could confirm the association between TAM infiltration, 
tumor progression and grading. In analogy to our findings, Wei and colleagues in 
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2014 reported a positive association between TAM infiltration and recurrence in a 
small cohort of 38 patients after curative resection of NFPNETs 20. In this report, 
TAM infiltration was only compared semiquantitatively. In contrast, in our series 
comprising more than 100 human samples TAM infiltration was quantified in absolute 
numbers per HPF which to our knowledge represents the largest study on TAMs in 
human PNET tissues.  
In various cancer models TAMs have been shown to affect angiogenesis 33. TAMs 
secrete a variety of proangiogenic growth factors, most prominently the vascular 
endothelial growth factor (VEGF), a cardinal mediator of tumor angiogenesis 34, 35.
TAMinduced upregulation of VEGF results in the socalled angiogenic switch that 
leads to enhanced microvessel formation and tumor progression. Our study clearly 
corroborate these findings showing a significantly reduced microvessel density 
following macrophage depletion.  
Clodronate coated in liposomes has been widely used as experimental tool for 
macrophage depletion in several disease models including autoimmune disorders, 
atherosclerosis and cancer 36. The use of liposomal clodronate has been reported in 
several xenograft tumor models 37, 38. Recently, we depleted TAMs by liposomal 
clodronate in a mouse model of pancreatic adenocarcinoma (PDAC) 29. Interestingly, 
in this model liposomal clodronate induced a significant decrease in metastasis 
formation. The size of the primary tumor, however, was only reduced to a minor 
extent 29. We speculate that different angiogenic patterns in PDAC versus PNET 
might be responsible for this difference: PDAC primary tumors are largely 
hypovascular which limit the antiangiogenic effect of liposomal clodronate on the 
primary tumor. In these tumors, the effect of premetastatic niches in target organs 
liver and lung might be more important. In contrast, PNET tissues are highly 
vascularized resulting in an increased efficacy of antiangiogenic strategies in PNET 
tumors including therapeutic targeting of TAMs.  
The depletory effect on macrophages appears to be a group effect and not to be 
restricted to liposomalencapsulated clodronate. It has also been observed with other 
bisphosphonates such as zoledronate which has been shown to reduce viability of 
macrophages without affecting cancer cells   and to diminish intratumoral 
macrophages in xenograft models  39, 40. However, liposomal coating of drugs 
such as clodronate enhances their phagocytosis by cells such as macrophages, 
thereby increasing therapeutic efficacy. Generally, nanoparticlecoating of cytotoxic 
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drugs such as doxorubicin or irinotecan with liposomes is increasingly used to 
decrease toxicity and improve tolerability 41, 42. However, human data on clodronate 
in neuroendocrine tumors are not available and the liposomal formulation has not 
been approved, yet. Thus, only conclusions from secondgeneration 
bisphosphonates can be drawn.  
Despite of the pronounced effects of liposomal clodronate action on microvessel 
density and tumor progression, we failed to detect a significant synergism of 
liposomal clodronate with the antiangiogenic multikinase inhibitor sunitinib, which has 
been shown to target several VEGFdependent signaling pathways   and to 
significantly improve progressionfree survival in PNET patients. This is in contrast to 
a report using xenograft HCC mouse models in which zoledronate was shown to 
overcome sunitinib and sorafenibinduced IL12dependent prometastatic resistance 
mechanisms 43. The reasons for the lack of synergism in our  model have yet 
to be elucidated. Previously, we have shown that liposomal clodronate leads to a 
pronounced downregulation of VEGF as main secretion product of TAM 29. It may be 
speculated that both macrophage depletion and sunitinib application predominantly 
affect VEGFdependent angiogenic pathways which could explain in part the lack of 
synergism in the highly VEGFdependent PNET model.  
Transgenic mouse models are an integral part of modern cancer research, however, 
the RIP1Tag2 model present some limitations in order to avoid general translation 
into the human system. From a biological point of view this model reflects higher 
proliferative tumors including NET G2 and G3 as well as poorlydifferentiated 
carcinomas NEC G3 21, 27. Furthermore, the tumorigenesis in the RIP1Tag2 model 
does not include metastatic disease, although some groups demonstrated a 
metastatic spread upon treatment with targeted therapies 30. In our hands, systematic 
evaluation of liver burden was excluded using SV40Tantigen antibody. Regarding 
functionality, not all tumors can release insulin, however, all mice suffer from 
hypoglycemia as tumorrelated cause of death. To this end, preclinical trials in this 
model must be designed to address pivotal challenges for higher proliferative 
pancreatic neuroendocrine tumors, whether functional active or not.      
Taken together, our data indicate that TAM play a major role in tumor progression of 
pancreatic neuroendocrine tumors. Pharmacological macrophage depletion by 
liposomal clodronate leads to a pronounced antiangiogenic effect decreasing 
tumorigenesis and tumor progression, which could represent a new therapeutic 
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avenue for this highly angiogenic tumor entity. Based on our data, further studies are 
warranted to evaluate the role of bisphosphonates alone or in combination with 
established therapies such as somatostatin analogues or cytotoxic drugs in 
pancreatic neuroendocrine tumors.  
  
);	
)2
Baseline characteristics of patients with nonmetastatic NFPNET primary tumors, 
insulinomas and metastatic NFPNET. 
Abbreviations: NF, nonfunctional active; PNET, pancreatic neuroendocrine tumor; G, 
grading; R, resection; M, metastases; SMS, somatostatin; SSA, somatostatin 
analogues 
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Age at surgery (years) 
 Median 
 Range 
 
54 
3079 
  
48 
1872 
  
58 
3173 
 
Tumor differentiation 
 Welldifferentiated 
 
11 
 
100% 
 
21 
 
100% 
 
18 
 
100% 
Grading 
 G1 
 G2 
 
9 
2 
 
82% 
18% 
 
21 
0 
 
100% 
 
1 
12 
 
8% 
92% 
RStatus 
 R0 
 R1 
 
11 
0 
 
100% 
0% 
 
19 
2 
 
90.5% 
9.5% 
  
MStatus 
 M0 
 M1 
 
11 
0 
 
100% 
0% 
 
11 
0 
 
100% 
0% 
 
0 
13 
 
0% 
100% 
Recurrencefree survival in 
months 
 Median 
 Range 
 
 
44 
5133 
  
 
9 
315 
   
CD68 positive cells 
 Average 
 Range 
 
170 
13
367 
  
163 
31
809 
   
Sites of metastasis       
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 Liver 
 LN 
13 
9 
100% 
69% 
SMSStatus 
 Positive 
     
12 
 
92% 
Surgical intervention 
 Primary resection 
 Metastatic surgery 
 No surgery  
     
9 
9 
3 
 
69% 
69% 
23% 
Medical treatment 
 SSA 
 Chemotherapy 
 Chemoembolization 
     
8 
13 
4 
 
61.5% 
100% 
30.7% 
CD68 positive cells 
 Primaries  
  Average  
  Range 
 Metastases 
  Average  
  Range 
     
133 
107151 
 
430 
1081251 
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Results of the prevention and intervention trial in mice being treated with liposomal 
clodronate or PBSLiposomes.  
Abbreviations: SD, standard deviation 
 
)    
Features Prevention Trial  Intervention Trial  
 PBS
Liposomes 
Clodronate 
Liposomes 
 PBS
Liposomes 
Clodronate 
Liposomes 
 
 mean SD mean SD P
value 
mean SD mean SD P
value 
Number of 
tumors 
10.3 1.4 13.0 1.9 0.27 13.0 2.6 10.7 1.2 0.41 
Number of 
invasive 
tumors 
2.7 0.4 1.6 0.5 0.1 4.6 1.2 2.2 0.4 0.069 
Prevalence 
of invasive 
tumors 
>>=  *>=  >1>( 100%  100%  1.0 
Tumor area 
in µm² 
*1?
'>*
1/
'>*
1-
'>*
>1?'
>*
>1>"* 12.7 
x106 
2.2 
x106 
10.2 
x106 
2.5x 
106 
0.47 
Ki67 index 
in invasive 
tumors 
58% 3% 48% 6% 0.11 60% 3% 60 5% 0.99 
CD31 
positive 
76.8 7.9 47.9 13.6 0.08 "?1 1 1 "1? >1>>*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cells per 
HPF 
Caspase 3 
positive 
cells per 
HPF 
10.6 1.3 10.6 2.4 0.99 22.1 6.7 15.5 2.7 0.36 
CD3 
positive 
cells per 
HPF 
10.2 2.6 7.1 1.7 0.35 ?1" 1 (1 1 >1>"&
FOXP3 
positive 
cells per 
HPF 
3.1 1.1 3.1 0.7 0.97 4.4 0.4 10.1 2.7 0.091 
Arginase 
positive 
cells per 
HPF 
4.8 0.9 7.1 1.3 0.16 10.5 1.8 9.6 2.0 0.75 
 
 
)"2
Results of the sunitinib monotherapy arm and the combination treatment of liposomal 
clodronat and sunitinib in an intervention setting. 
Abbreviations: SD, standard deviation 
 
)"    
Features Sunitinib monotherapy  Combination Treatment  
 DMSO Sunitinib  DMSO + 
PBS
Liposomes 
Sunitinib + 
Clodronate 
Liposomes 
 
 mean SD mean SD P
value 
mean SD mean SD P
value 
Number of 
tumors 
8.9 1.9 12.6 2.3 0.25 16.7 3.1 17.3 3.6 0.89 
Number of 
invasive 
tumors 
3.4 0.7 4.4 0.9 0.43 4.8 0.5 4.0 0.9 0.5 
Prevalence 
of invasive 
tumors 
100%  100%  1.0 100%  100%  1.0 
Tumor area 
in µm² 
10.6 
x106 
2.3 
x106 
10.3 
x106 
2.6x 
106 
0.92 16.1 
x106 
2.4 
x106 
11.6 
x106 
3.2x 
106 
0.32 
Ki67 index 
in invasive 
tumors 
70% 3% 65% 5% 0.42 72% 4% 77% 3% 0.32 
CD31 
positive 
""1 1? *1" 1& >1>>& "?1 1- &1* 1- >1>>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cells per 
HPF 
F4/80 
positive 
cells per 
HPF 
30.7 4.7 23.3 3.8 0.24 &"1? &1 "1& 1- >1>>"
Caspase 3 
positive 
cells per 
HPF 
15.6 3.1 16.7 3.6 0.82 18.9 5.3 24.1 3.8 0.43 
CD3 
positive 
cells per 
HPF 
19.5 3.3 14.1 1.8 0.14 22.8 4.5 19.6 3.5 0.59 
FOXP3 
positive 
cells per 
HPF 
7.1 1.5 7.3 1.7 0.92 7.6 2.1 4.6 1.1 0.19 
Arginase 
positive 
cells per 
HPF 
5.4 1.4 4.2 0.9 0.49 *1& 1 1* 1& >1>/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Clinical and pathological features of patients with benign and malignant insulinomas. 
 
;	2
TAM infiltration correlates with malignant features of human PNETs. (A) Scheme of 
tissue included from patients with distinct functionality, stage and grading. Besides 
whole sections of paraffin blocks, a MTA carrying tissue of 83 insulinomas (including 
metastasis) was included. (B) Representative immunohistochemistry of CD68 
positive cells in sections from PNETs and corresponding HE sections were shown 
with 40x original magnificantion. (C) Quantification of CD68 positive cells in whole 
paraffin sections (left) of 21 insulinomas, 11 nonmetastatic NFPNETs, 4 primaries 
of metastatic PNETs and 14 distant metastases. Data shown as mean ± SD. 
Symbols: dots represent data from each tissue; black horizontal line, mean 
percentage for each group.  
 
;	2
TAM infiltration in a MTA of human insulinomas. (A) 200fold magnification of 
representative CD68 positive cells in normal pancreas, benign, malignant and 
metastasis. (B) Quantification of CD68 density in the insulinoma MTA (middle and 
Page 17 of 26
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
right). 19 normal pancreata were compared to 45 benign and 11 malignant 
insulinomas (middle). Fractions of malignant insulinomas with their sites of 
metastases were added at the right figure with 7 primary malignant insulinomas, 5 
lymph node and 7 liver metastases. Data shown as mean ± SD. Symbols: dots 
represent data from each tissue; black horizontal line, mean percentage for each 
group.  
 
;	"2
Liposomal clodronate decelerated tumor progression 
 and 
. (A) Human 
pancreatic neuroendocrine tumor cell lines Bon1 and QGP1 were treated with PBS
Liposomes, 0.1mg and 1mg liposomal clodronate for 24h. Similarly, the myeloid cell 
lines J774, RAW and murine bone marrowderived macrophages (mBMM) from non
transgenic mice were treated uniquely. Assays were performed in triplicate and cell 
viability was determined by ATPbased assay. Data are presented as mean ± SD and 
are representative of three independent experiments.  
 
;	&2
(A) Treatment scheme of the prevention (week 613) and intervention (week 916) 
trial. Liposomal clodronate or PBSLiposomes were applied intraperitoneal in 
RIP1Tag2 mice biweekly. (B) Treatment scheme of sunitnib monotherapy (week 12
16) daily given per os and the combination of sunitinib and liposomal clodronate 
(week 916), which was administered biweekly intraperitoneal compared to DMSO 
and PBSLiposomes as control arm. 
 
))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2
TAM infiltration correlates with proliferation and angiogenesis during tumor 
progression in the RIP1Tag2 model. (A) Representative immunohistochemistry of 
HE, F4/80, Ki67 and CD31 positive cells in distinct stages of the RIP1Tag2 
tumorigenesis including hyperplastic, angiogenic and invasive tumors. 40x original 
magnificantion is presented. (B) F4/80 positive cells per HPF were counted in 25 
hyperplastic, 12 angiogenic and 15 invasive islets. (C) Ki67 index in % was 
measured in 17 hyperplastic, 22 angiogenic and 18 invasive islets. (D) CD31 positive 
cells per HPF were counted in 16 hyperplastic, 20 angiogenic and 20 invasive 
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tumors. Data shown as mean ± SD. Symbols: dots represent data from each islet; 
black horizontal line, mean percentage for each group. 
 
));	2
TAM infiltration decreases upon liposomal clodronate therapy. All macrophages were 
counted and afterwards normalized to all islets in the tumor. Median TAM infiltration 
normalized to all islets was 22 +/ 3.7 SD in the PBSLiposomes group compared to 
12 +/ 2.2 in the clodronate arm for the prevention trial (P=0.044). 65 +/ 6.7 SD 
(PBSLiposomes) and 22 +/ 4.7 (clodronate) were the results for the intervention 
group, respectively (P=0.0007)).   
 
 
));	"2
Representative immunohistochemistry of Caspase 3, CD3, FOXP3 and Arginase 
positive cells in distinct stages of the RIP1Tag2 tumorigenesis including hyperplastic, 
angiogenic and invasive tumors. 40x original magnificantion is presented. Positive 
cells were counted in at least 10 HPF. Positive cells in lymph nodes served as 
internal control.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